05/08 Federman & Sherwood Investigates CytoDyn Inc. for Possible Violations of Federal Securities Laws
Oklahoma City, OK (May 8, 2020) – The law firm of Federman & Sherwood has initiated an investigation into CytoDyn Inc. [OTC: CYDY] and its officers and directors, with respect to possible violations of federal securities laws. On April 27, 2020, CytoDyn, a late-stage biotechnology company, issued a press release indicating it had submitted a “Biologics License Application (“BLA”) to the U.S. Food and Drug Administration for Leronlimab as a combination therapy with HAART for highly treatment experienced HIV patients.” On May 7, 2020, CytoDyn announced that its BLA for Leronlimab “will be considered completed after the clinical datasets are […]